Evidence map›Paper›PMID 20832999›Full record

ArticleJournal of dermatological science2010

The potential use of protein kinase D inhibitors for prevention/treatment of epidermal tumors.

Senthil Nathan Arun, Ding Xie, M Ernest Dodd, Xiaofeng Zhong, Wendy B Bollag

Open access · greenAbstract read
In one paragraph

Article in Journal of dermatological science, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Role of Resveratrol in Regulating Cutaneous Functions.Evidence-based complementary and alternative medicine : eCAM · 2020
    Review
  3. Article
  4. Article
  5. Ultraviolet activation of PKD: implications for skin cancer.Future oncology (London, England) · 2011
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Senthil Nathan ArunInstitute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, GA 30912, USA.
Ding Xie
M Ernest Dodd
Xiaofeng Zhong
Wendy B Bollag
Augusta University · US

Funding

PHOSPHOLIPASE D AND KERATINOCYTE DIFFERENTIATIONR01AR045212 · NIAMS · MEDICAL COLLEGE OF GEORGIA (MCG) · PI BOLLAG, WENDY B · 1999 to 2007
$1.1M
Protein Kinase D and Epidermal Structure and FunctionR21AR057321 · NIAMS · AUGUSTA UNIVERSITY · PI BOLLAG, WENDY B · 2009 to 2010
$362k
PHOSPHOLIPASE D AND KERATINOCYTE DIFFERENTIATIONR29AR045212 · NIAMS · MEDICAL COLLEGE OF GEORGIA (MCG) · PI BOLLAG, WENDY B · 1998 to 1998
–
NIAMS NIH HHS AR45212NIAMS NIH HHS AR57321NIAMS NIH HHS R01 AR045212NIAMS NIH HHS R21 AR057321
6 · The paper itself

Abstract

backgroundThe serine/threonine kinase protein kinase D (PKD) has been proposed to be a pro-proliferative, anti-differentiative signal in epidermal keratinocytes. Indeed, the phorbol ester tumor promoter, 12-O-tetradecanoylphorbol 13-acetate (TPA) induces biphasic PKD activation, which mirrors the biphasic response of initial differentiation followed by proliferation and tumor promotion seen in TPA-treated keratinocytes in vitro and epidermis in vivo.

objectiveOur objective was to test the idea that PKD's pro-proliferative and/or anti-differentiative effects in keratinocytes contribute to TPA-induced tumorigenesis.

methodsUsing western analysis and assays of keratinocyte proliferation and differentiation, we investigated the effect of inhibitors of PKD on keratinocyte function.

resultsWe found that overexpression of a constitutively active PKD mutant increased, and of a dominant-negative PKD mutant decreased, keratinocyte proliferation. A recently described selective PKD inhibitor showed low potency to inhibit keratinocyte proliferation or PKD activation. Therefore, we tested the ability of known only relatively selective PKD inhibitors on keratinocyte function and protein kinase activation. H89 {N-[2-(p-bromocinnamylamino) ethyl]-5-isoquinoline-sulfonamide}, a reported inhibitor of PKD and cAMP-dependent protein kinase, enhanced the effect of a differentiating agent on a marker of keratinocyte differentiation. Another reported non-selective PKD inhibitor, resveratrol stimulated differentiation and inhibited proliferation. The protein kinase C/PKD inhibitor Gö6976 blocked the increase in proliferation (as measured by DNA specific activity) induced by chronic TPA without affecting the initial TPA-elicited differentiation.

conclusionOur results support the idea that relatively selective PKD inhibitors, such as Gö6976, H89 and resveratrol, might be useful for preventing/treating epidermal tumorigenesis without affecting keratinocyte differentiation.

Indexed as

AnimalsAnticarcinogenic AgentsCarbazolesCell DifferentiationCell ProliferationCells, CulturedEpidermisIsoquinolinesKeratinocytesMiceProtein Kinase CProtein Kinase InhibitorsResveratrolSkin NeoplasmsStilbenesSulfonamidesAnticarcinogenic AgentsCarbazolesGo 6976IsoquinolinesN-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamideProtein Kinase Cprotein kinase DProtein Kinase InhibitorsResveratrolStilbenesSulfonamidesTetradecanoylphorbol Acetate

Identifiers

PMID20832999
PMCPMC2965187
OpenAlexW2158883148

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.